Koers Antibe Therapeutics Inc Toronto S.E.
Aandelen
ATE
CA0370251039
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 15,64 mln. 21,29 mln. 14,41 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 91,46% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Alain Wilson
DFI | Director of Finance/CFO | - | 01-12-15 |
Chief Tech/Sci/R&D Officer | - | - | |
Ana Stegic
CTO | Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 50 | 24-11-20 | |
Amal Khouri
BRD | Director/Board Member | - | 19-03-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+11,60% | 106 mld. | |
-4,68% | 24,28 mld. | |
-0,82% | 21,96 mld. | |
-10,12% | 18,16 mld. | |
-42,12% | 16,37 mld. | |
-17,47% | 15,56 mld. | |
+2,77% | 13,63 mld. | |
+34,58% | 12,27 mld. | |
+77,64% | 8,87 mld. |